CHMP5 and myeloid sarcoma: In conclusion, the results of this epidemiological cohort study showed that patients with MS, who were either treated with a DMT or not, were able to produce high titers of spike-protein-related antibodies and sufficient neutralizing activity after SARS-CoV-2 vaccinations.